RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jose L. Lopez-Ribot to Candidiasis

This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Candidiasis.
Connection Strength

8.589
  1. Ajetunmobi OH, Wall G, Bonifacio BV, Montelongo-Jauregui D, Lopez-Ribot JL. A 384-Well Microtiter Plate Model for Candida Biofilm Formation and Its Application to High-Throughput Screening. Methods Mol Biol. 2023; 2658:53-64.
    View in: PubMed
    Score: 0.832
  2. Wall G, Chen E, Hull MV, Lopez-Ribot JL. Screening the CALIBR ReFRAME Library in Search for Inhibitors of Candida auris Biofilm Formation. Front Cell Infect Microbiol. 2020; 10:597931.
    View in: PubMed
    Score: 0.720
  3. Romo JA, Pierce CG, Chaturvedi AK, Lazzell AL, McHardy SF, Saville SP, Lopez-Ribot JL. Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation. mBio. 2017 Dec 05; 8(6).
    View in: PubMed
    Score: 0.586
  4. Pierce CG, Srinivasan A, Ramasubramanian AK, L?pez-Ribot JL. From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiol Spectr. 2015 Jun; 3(3).
    View in: PubMed
    Score: 0.492
  5. Uppuluri P, Chaturvedi AK, Jani N, Pukkila-Worley R, Monteagudo C, Mylonakis E, K?hler JR, Lopez Ribot JL. Physiologic expression of the Candida albicans pescadillo homolog is required for virulence in a murine model of hematogenously disseminated candidiasis. Eukaryot Cell. 2012 Dec; 11(12):1552-6.
    View in: PubMed
    Score: 0.411
  6. Chaturvedi AK, Lazzell AL, Saville SP, Wormley FL, Monteagudo C, Lopez-Ribot JL. Validation of the tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease. PLoS One. 2011; 6(5):e20449.
    View in: PubMed
    Score: 0.372
  7. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, K?hler JR, Kadosh D, Lopez-Ribot JL. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 2010 Mar 26; 6(3):e1000828.
    View in: PubMed
    Score: 0.343
  8. Uppuluri P, Pierce CG, L?pez-Ribot JL. Candida albicans biofilm formation and its clinical consequences. Future Microbiol. 2009 Dec; 4(10):1235-7.
    View in: PubMed
    Score: 0.336
  9. Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother. 2009 Sep; 64(3):567-70.
    View in: PubMed
    Score: 0.327
  10. Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis. Clin Vaccine Immunol. 2009 Mar; 16(3):430-2.
    View in: PubMed
    Score: 0.316
  11. Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun. 2008 Jan; 76(1):97-102.
    View in: PubMed
    Score: 0.291
  12. Thomas DP, Viudes A, Monteagudo C, Lazzell AL, Saville SP, L?pez-Ribot JL. A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. Proteomics. 2006 Nov; 6(22):6033-41.
    View in: PubMed
    Score: 0.271
  13. Ramage G, Saville SP, Thomas DP, L?pez-Ribot JL. Candida biofilms: an update. Eukaryot Cell. 2005 Apr; 4(4):633-8.
    View in: PubMed
    Score: 0.243
  14. L?pez-Ribot JL, Casanova M, Murgui A, Mart?nez JP. Antibody response to Candida albicans cell wall antigens. FEMS Immunol Med Microbiol. 2004 Jul 01; 41(3):187-96.
    View in: PubMed
    Score: 0.231
  15. Monteagudo C, Viudes A, Lazzell A, Martinez JP, Lopez-Ribot JL. Tissue invasiveness and non-acidic pH in human candidiasis correlate with "in vivo" expression by Candida albicans of the carbohydrate epitope recognised by new monoclonal antibody 1H4. J Clin Pathol. 2004 Jun; 57(6):598-603.
    View in: PubMed
    Score: 0.230
  16. Viudes A, Lazzell A, Perea S, Kirkpatrick WR, Peman J, Patterson TF, Martinez JP, L?pez-Ribot JL. The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis. FEMS Microbiol Lett. 2004 Mar 19; 232(2):133-8.
    View in: PubMed
    Score: 0.226
  17. Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell. 2003 Oct; 2(5):1053-60.
    View in: PubMed
    Score: 0.219
  18. Redding SW, Kirkpatrick WR, Saville S, Coco BJ, White W, Fothergill A, Rinaldi M, Eng T, Patterson TF, Lopez-Ribot J. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol. 2003 Feb; 41(2):619-22.
    View in: PubMed
    Score: 0.209
  19. Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1999 Jul; 43(7):1621-30.
    View in: PubMed
    Score: 0.163
  20. Wall G, Montelongo-Jauregui D, Vidal Bonifacio B, Lopez-Ribot JL, Uppuluri P. Candida albicans biofilm growth and dispersal: contributions to pathogenesis. Curr Opin Microbiol. 2019 12; 52:1-6.
    View in: PubMed
    Score: 0.162
  21. Liu NN, Uppuluri P, Broggi A, Besold A, Ryman K, Kambara H, Solis N, Lorenz V, Qi W, Acosta-Zald?var M, Emami SN, Bao B, An D, Bonilla FA, Sola-Visner M, Filler SG, Luo HR, Engstr?m Y, Ljungdahl PO, Culotta VC, Zanoni I, Lopez-Ribot JL, K?hler JR. Intersection of phosphate transport, oxidative stress and TOR signalling in Candida albicans virulence. PLoS Pathog. 2018 07; 14(7):e1007076.
    View in: PubMed
    Score: 0.153
  22. Romo JA, Pierce CG, Esqueda M, Hung CY, Saville SP, Lopez-Ribot JL. In Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formation. Front Cell Infect Microbiol. 2018; 8:227.
    View in: PubMed
    Score: 0.153
  23. Vila T, Romo JA, Pierce CG, McHardy SF, Saville SP, Lopez-Ribot JL. Targeting Candida albicans filamentation for antifungal drug development. Virulence. 2017 02 17; 8(2):150-158.
    View in: PubMed
    Score: 0.132
  24. Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. Virulence. 2017 02 17; 8(2):138-142.
    View in: PubMed
    Score: 0.132
  25. Albataineh MT, Lazzell A, Lopez-Ribot JL, Kadosh D. Ppg1, a PP2A-type protein phosphatase, controls filament extension and virulence in Candida albicans. Eukaryot Cell. 2014 Dec; 13(12):1538-47.
    View in: PubMed
    Score: 0.118
  26. Pierce CG, Lopez-Ribot JL. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov. 2013 Sep; 8(9):1117-26.
    View in: PubMed
    Score: 0.107
  27. Martins M, Lazzell AL, Lopez-Ribot JL, Henriques M, Oliveira R. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J Basic Microbiol. 2012 Aug; 52(4):487-91.
    View in: PubMed
    Score: 0.096
  28. Lee SA, Jones J, Hardison S, Kot J, Khalique Z, Bernardo SM, Lazzell A, Monteagudo C, Lopez-Ribot J. Candida albicans VPS4 is required for secretion of aspartyl proteases and in vivo virulence. Mycopathologia. 2009 Feb; 167(2):55-63.
    View in: PubMed
    Score: 0.077
  29. Grubb SE, Murdoch C, Sudbery PE, Saville SP, Lopez-Ribot JL, Thornhill MH. Candida albicans-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. Infect Immun. 2008 Oct; 76(10):4370-7.
    View in: PubMed
    Score: 0.076
  30. Thomas DP, Pitarch A, Monteoliva L, Gil C, Lopez-Ribot JL. Proteomics to study Candida albicans biology and pathogenicity. Infect Disord Drug Targets. 2006 Dec; 6(4):335-41.
    View in: PubMed
    Score: 0.068
  31. Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother. 2006 Oct; 50(10):3312-6.
    View in: PubMed
    Score: 0.067
  32. Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis. 2006 Apr 01; 193(7):1014-22.
    View in: PubMed
    Score: 0.065
  33. Hernandez S, L?pez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004 Apr; 48(4):1382-3.
    View in: PubMed
    Score: 0.057
  34. Viudes A, Pem?n J, Cant?n E, Ubeda P, L?pez-Ribot JL, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis. 2002 Nov; 21(11):767-74.
    View in: PubMed
    Score: 0.051
  35. Viudes A, Cant?n E, Pem?n J, L?pez-Ribot JL, Gobernado M. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis]. Rev Esp Quimioter. 2002 Mar; 15(1):32-42.
    View in: PubMed
    Score: 0.049
  36. Redding SW, Bailey CW, Lopez-Ribot JL, Kirkpatrick WR, Fothergill AW, Rinaldi MG, Patterson TF. Candida dubliniensis in radiation-induced oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun; 91(6):659-62.
    View in: PubMed
    Score: 0.047
  37. Monteagudo C, Lopez-Ribot JL, Murgui A, Casanova M, Chaffin WL, Martinez JP. Immunodetection of CD45 epitopes on the surface of Candida albicans cells in culture and infected human tissues. Am J Clin Pathol. 2000 Jan; 113(1):59-63.
    View in: PubMed
    Score: 0.042
  38. Banerjee M, Lazzell AL, Romo JA, Lopez-Ribot JL, Kadosh D. Filamentation Is Associated with Reduced Pathogenicity of Multiple Non-albicans Candida Species. mSphere. 2019 10 16; 4(5).
    View in: PubMed
    Score: 0.042
  39. Dekkerov? J, Lopez-Ribot JL, Bujd?kov? H. Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen. Eur J Clin Microbiol Infect Dis. 2019 Jan; 38(1):101-108.
    View in: PubMed
    Score: 0.039
  40. Carlisle PL, Banerjee M, Lazzell A, Monteagudo C, L?pez-Ribot JL, Kadosh D. Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):599-604.
    View in: PubMed
    Score: 0.020
  41. Banerjee M, Thompson DS, Lazzell A, Carlisle PL, Pierce C, Monteagudo C, L?pez-Ribot JL, Kadosh D. UME6, a novel filament-specific regulator of Candida albicans hyphal extension and virulence. Mol Biol Cell. 2008 Apr; 19(4):1354-65.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support